In a move toward non-addictive pain management, Acertara Acoustic Laboratories is in collaboration with Vanderbilt University Institute of Imaging Sciences and the National Institute of Neurological Disorders and Stroke (NINDS). This partnership is geared towards developing a focused ultrasound stimulation system, an alternative to opioid treatments for neuropathic pain caused by stroke-related nerve damage.
“Acertara, an ISO/IEC 17025:2017 accredited and ISO13485:2016 certified leader in medical ultrasound technology, brings its R&D and regulatory expertise to the forefront as a part of the effort to develop and bring this technology to market. The ultrasound system, guided by magnetic resonance imaging (MRI), is designed to target and modulate neural activity deep in the brain, providing relief for the often-debilitating sensations experienced by neuropathic pain sufferers,” according to a press release.
The initiative to obviate or mitigate conventional opioid-based treatments, which offer limited relief and pose a high risk of addiction, aligns with Acertara’s commitment to developing innovative health care solutions through ultrasound. The development phase of this project is supported by a three-year grant from the National Institutes of Health under the HEAL (Helping to End Addiction Long-term) initiative. The focus of phase one will be to develop the technology necessary to overcome historical technical barriers related to transcranial ultrasound, and ready the system for a pilot clinical trial.
Levi Moore, president and CEO of Acertara, expressed enthusiasm about the venture.
“This collaboration represents a significant milestone in our mission to advance ultrasound technology for new therapeutic applications. We are excited about the potential of this device to transform pain management and offer a safe, effective alternative to opioids,” Moore said.
The team leading Acertara’s efforts includes G. Wayne Moore and Dr. Wilder Iglesias. Vanderbilt University Institute of Imaging Science, the grant recipient, and inventor of the device, is headed by lead investigator Dr. Charles Caskey.